Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Status:
Terminated
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
This study is multicenter, double-blinded parallel group design, where participants with
moderate to severe asthma with AFAD will be enrolled. Participants will receive three doses
of 10 milligrams/kilogram (mg/kg) of GSK3772847 every 4 Weeks versus placebo along with
standard of care. Participants will be randomized in 1:1 ratio to receive either 10 mg/kg
GSK3772847 intravenously (IV) or matching placebo IV. Participants will receive study
treatment on Week 0 (Day 1), Week 4 and Week 8. The total duration of the study will be 28
Weeks and approximately 46 participants will be randomized.